UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
August 02 2023 - 5:00PM
Business Wire
Conference Call and Webcast Scheduled for
Thursday, August 10, 2023 at 10:00 AM ET
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated
to developing and commercializing innovative solutions that treat
urothelial and specialty cancers, today announced that it will
report second quarter 2023 financial results on Thursday, August
10, 2023, prior to the open of the market. The announcement will be
followed by a live audio webcast and conference call at 10:00 AM
Eastern Time.
A live public webcast of the earnings conference call can be
accessed on UroGen’s Investor Relations website. Following the live
webcast, a replay will be available on the site for approximately
30 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and
commercializing innovative solutions that treat urothelial and
specialty cancers because patients deserve better options. UroGen
has developed RTGel® reverse-thermal hydrogel, a proprietary
sustained release, hydrogel-based platform technology that has the
potential to improve therapeutic profiles of existing drugs.
UroGen’s sustained release technology is designed to enable longer
exposure of the urinary tract tissue to medications, making local
therapy a potentially more effective treatment option. UroGen’s
first commercial product Jelmyto® (mitomycin) for pyelocaliceal
solution, and investigational treatment UGN-102 (mitomycin) for
intravesical solution for patients with low-grade non-muscle
invasive bladder cancer, are designed to ablate tumors by
non-surgical means. UroGen is headquartered in Princeton, New
Jersey with operations in Israel. Visit www.urogen.com to learn
more or follow us on Twitter,@UroGenPharma.
Jelmyto®, RTGel® and UroGen® are registered trademarks of UroGen
Pharma Ltd.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230802943779/en/
INVESTOR CONTACT: Vincent Perrone
vincent.perrone@urogen.com (609) 460-3588 MEDIA CONTACT:
Cindy Romano Cindy.romano@urogen.com (609) 460-3583
UroGen Pharma (NASDAQ:URGN)
Historical Stock Chart
From Apr 2024 to May 2024
UroGen Pharma (NASDAQ:URGN)
Historical Stock Chart
From May 2023 to May 2024